Abstract 2054
Background
Oncology patients with advanced disease frequently undergo Radiation to relieve symptoms such as pain and dyspnoea. These patients have been treated by different health professionals in multiple, complexed and long-term treatments. The goal of this study was to investigate the possibility to help and improve the quality of life of these patients.
Trial design
In the present study, 32 patients participated and were evaluated prospectively. The main criteria for their participation were the following: oncology patients >18 years old with a satisfactory level of verbal communication and advance cancer receiving radiotherapy. EORTC questionnaires (QLQ-C30) and questionnaire for problems and needs for palliative care PNCP-Center for the Quality of Care of the WOK research were used.The quality of life of these patients was assessed prior the beginning of the treatment and that was taken as a quality of life baseline level as well as at the end of their treatment. The present study was conducted from June 2018 to December 2018 in the Radiotherapy Department of "Hygeia" Hospital in Greece. Of the 32 patients who were evaluated 11 were women and 21 were men. Their average age was 65 years old. Also 84,4% of these patients had external help (family, caretaker). A significant improvement in the quality of life was observed only in patients who had home help for 4 hours daily (p.value 0,006).Men seemed to improve the quality of life after treatment (p.value 0,005).The patients reported their palliative care needs in the following rating scale: financial and phychological issues, autonomy, daily activities, spiritual issues, organic symptoms and need for information ,all of which will be presented in detail. Those who have difficulty completing tasks need or depent on others and ask for professional help (p.value 0,001)Radiation therapy alleviates the organic symptoms of patients with advanced disease, but it does not cover their needs that have become more important to them than their organic symptoms. Care for these patients needs a more specialized approach which incorporates the principles of palliative care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract